IHU INFINY - Institut des maladies inflammatoires chroniques de l'intestin

What IHU INFINY - Institut des maladies inflammatoires chroniques de l'intestin does

IHU Infiny is a French non-profit University Hospital Institute (Institut Hospitalo-Universitaire) established in 2023 under the France 2030 national investment program, dedicated to inflammatory bowel diseases (IBD), principally Crohn's disease and ulcerative colitis. It is one of only 12 institutes awarded IHU status and is coordinated by CHRU de Nancy from the IRIS building on the Hôpitaux de Brabois site, federating 9 joint research units (Université de Lorraine, Inserm, CNRS, Institut Pasteur) and 3 clinical investigation centers. Its mandate spans four integrated pillars: fundamental and translational research, multidisciplinary clinical care, therapeutic patient education, and innovation transfer to the healthcare economy.

The institute's principal product surface centers on the RHU i-DEAL digital care pathway (ANR-23-RHUS-0016), launched in June 2024, which combines a home monitoring application integrating non-invasive biomarkers with predictive algorithms for early Crohn's flare detection, supported by four novel multiparametric MRI sequences for precision intestinal imaging and remote ultrasound diagnostics. Complementing this, EDU MICILOR delivers therapeutic patient education across Nancy CHRU with over 200 healthcare professionals involved, while FUTURES (annual international symposium) and the NGERE-co-organized MICI Autumn School anchor research dissemination and training. The AddiMapping project (PEPR SAMS award) extends capability into microbiome and food systems research.

The business model is that of a publicly funded, non-profit research consortium with no commercial pricing on patient services, which are delivered within the French public healthcare system. Revenue mechanics consist of multi-year France 2030 / ANR grants (including the RHU i-DEAL tranche and the AddiMapping PEPR SAMS award), institutional co-funding from Région Grand Est and Métropole du Grand Nancy, donations and corporate sponsorship channeled through Fondation ID+ Lorraine (with French tax deduction benefits), industrial partnership contracts (Siemens Healthineers, Docaposte, StemInov), and downstream research valorization via patents, licenses, and potential startup creation. Patient monitoring services are not commercialized; monetization, where it occurs, runs through research valorization and technology transfer rather than direct billing.

Name

IHU INFINY - Institut des maladies inflammatoires chroniques de l'intestin

Legal name

IHU INFINY

Website

https://ihu-infiny.fr

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Medical Research Institute

NAICS

Hospitals (622), Ambulatory Health Care Services (621), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Inflammatory Bowel Disease (IBD) Care (HLAKAEAD)

akta.pro secondary industry

General Gastroenterology (HLAKAEAA)

Keywords

• Inflammatory bowel disease research
• University hospital institute
• Digital care pathways
• Therapeutic patient education
• Clinical investigation centers

Headquarters

HQ city

Vandœuvre-lès-Nancy

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Government Funding (France 2030): Primary funding from the France 2030 investment program as one of 12 university hospital institutes created in 2023. Funded through ANR (Agence Nationale de la Recherche) for RHU i-DEAL project.
2. Donations and Sponsorship: Individual and corporate donations through Fondation ID+ Lorraine, with tax benefits for donors (66% income tax deduction, 75% IFI deduction for individuals; 60% corporate tax deduction for sponsors).
3. Institutional Partnerships: Strategic partnerships with industrial partners for collaborative research projects, including funding from companies engaging in health innovation.
4. Research Valorization: Transfer of research results into concrete solutions through innovation initiatives, potentially generating revenue through patents, licenses, or startup creation.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

IHU INFINY is a University Hospital Institute dedicated to inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. It delivers an integrated mission of research, patient care, education, and innovation, operating a digital care pathway (RHU i-DEAL), a therapeutic patient education program (EDU MICILOR), and coordinated clinical and translational research across nine joint research units and three clinical investigation centers.

Product overview

IHU Infiny is a University Hospital Institute serving as a single unified platform for Inflammatory Bowel Disease research, care, education, and innovation. The core offering includes the RHU i-DEAL digital care pathway (a technology-enabled program for home-based monitoring and precision imaging), and EDU MICILOR, a therapeutic patient education module. These are complemented by fundamental/translational research programs, clinical investigation, and training initiatives - all unified under the IHU Infiny umbrella to advance understanding and management of Crohn's disease and ulcerative colitis.

Differentiator

Problem solved

Functional benefit

Brands

• RHU i-DEAL: Research Hospital University project for digital care pathway and home monitoring for Crohn's disease patients
• EDU MICILOR
• FUTURES
• MICI Autumn School

Products and services

• RHU i-DEAL Digital Care Pathway A digital care pathway program for Crohn's disease patients that combines remote symptom monitoring with personalized treatment adjustment by healthcare teams, intended for adult patients followed at participating expert IBD centers.
• EDU MICILOR Therapeutic Patient Education Program A therapeutic patient education program for adults living with inflammatory bowel disease, delivered in workshops by trained healthcare professionals in collaboration with patient associations, to improve self-management and quality of life.

Quantifiable outcome

• 80% of RGAA accessibility criteria met
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

14 partnerships are on record, tiered flagship, core and minor.

• AFA Crohn RCH FranceflagshipStrategic or Co-development Partner · 1 January 202443-year-old patient association supporting people with IBD. Key partner for patient support, research funding, and awareness activities. Co-organizes World IBD Day events and conferences.
• GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives)flagshipStrategic or Co-development Partner · 1 January 2024Strategic partnership announced for clinical research collaboration in IBD. GETAID represented by President David Laharie.
• StemInovcoreStrategic or Co-development Partner · 1 January 2024Innovation partner represented by CEO Julie Hutin, focused on stem cell research and therapeutic development for IBD.
• CHRU de Nancy (Nancy University Hospital)coreStrategic or Co-development Partner · 1 January 2023Primary institutional partner and host of IHU Infiny. CHRU de Nancy provides clinical infrastructure, healthcare professionals, and research facilities. The institute is located at Hôpitaux de Brabois site.
• Université de LorrainecoreStrategic or Co-development Partner · 1 January 2023Founding academic member providing research expertise, faculty, and academic programs. Hosts multiple joint research units with IHU Infiny.
• Inserm (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development Partner · 1 January 2023National health research institute providing scientific expertise and funding. Co-directs multiple research units within the IHU.
• Métropole du Grand NancycoreStrategic or Co-development Partner · 1 January 2023Regional metropolitan authority providing local government support and strategic alignment for healthcare innovation.
• Institut PasteurcoreStrategic or Co-development PartnerCo-directs research through Benoît Chassaing's Microbiome-Host Interactions group. Contributes to AddiMapping project under PEPR SAMS.
• NGERE (Nutrition, Génétique et Exposition aux Risques Environnementaux)coreStrategic or Co-development PartnerInserm-U Lorraine research laboratory U1256 conducting fundamental research on nutrition, genetics, and environmental risks in IBD. Co-organizes Autumn School.
• IADI (Imagerie Adaptative Diagnostique et Interventionnelle)coreTechnology or IntegrationResearch unit developing advanced MRI imaging techniques for IBD diagnosis and characterization. Contributes to RHU i-DEAL imaging work packages.
• CIC-IT Nancy (Centre d'Investigation Clinique Innovation Technologique)coreTechnology or IntegrationClinical investigation center providing infrastructure for clinical trials and technological innovation in medical imaging.
• ID+ Lorraine FoundationcoreGTM or Marketing PartnerScientific cooperation foundation of University of Lorraine and Nancy CHRU. Manages donations and corporate sponsorship for IHU Infiny.
• Luxembourg Institute of HealthminorStrategic or Co-development PartnerInternational research partner for cross-border healthcare collaboration in IBD research.
• COOKALminorStrategic or Co-development PartnerNancy-based company developing aromatized cooking spray to restore taste pleasure for patients with eating/swallowing disorders. Collaboration for patient quality of life innovation.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Others

• Crohn's & Colitis Foundation: The largest US non-profit dedicated to IBD research, patient support, and advocacy. Comparable as an IBD-focused non-profit combining research funding, patient education, and awareness — a thematic adjacency to IHU Infiny's research-care-education-innovation mission.
• AbbVie (IBD franchise — Humira, Skyrizi, Rinvoq): Global pharmaceutical leader in IBD therapeutics and a potential industry partner for clinical trials and translational research. Thematically adjacent as the dominant commercial player serving the same patient population IHU Infiny researches.

Direct peers

• AFA Crohn RCH France: Flagship patient association partner of IHU Infiny and the leading French IBD patient organization with a 43-year history. Comparable as an IBD-focused organization that combines patient support, research funding, and awareness activities in the French market.
• IHU ICAN (Institut de Cardiométabolisme et Nutrition): Another France 2030 University Hospital Institute, focused on cardiometabolic disease. Highly comparable in structure, governance, public funding model, and integrated research-care-education-innovation mission, though operating in a different therapeutic area.
• IHU Méditerranée Infection: France 2030 IHU based in Marseille and one of the largest IHUs. Comparable as a peer IHU under the same funding program with a similar academic hospital consortium structure.
• GETAID (Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives): French clinical research consortium dedicated to IBD therapeutics and a strategic partner of IHU Infiny. Highly comparable as a French IBD-focused research network with overlapping clinical investigator base.

Broad incumbents

• Mount Sinai Gastroenterology (Dr. Henry D. Janowitz Division): Major US IBD specialty division and an institution represented on IHU Infiny's International Scientific Committee. Comparable as a leading IBD research and care center, though embedded in a much larger academic medical center.
• Mayo Clinic IBD Center: One of the largest and most established IBD specialty centers globally, offering integrated research, clinical care, and education. Comparable as a flagship IBD center but at much greater scale and as part of a broader multi-specialty health system.

Emerging players

• ECCO (European Crohn's and Colitis Organisation): The leading European professional organization focused on IBD, with overlapping scientific community, congress activities, and guideline development. Comparable as a stakeholder in shaping the European IBD research and clinical agenda.
• IOIBD (International Organization for the Study of Inflammatory Bowel Disease): International scientific organization convening leading IBD researchers, including figures aligned with IHU Infiny's scientific committee. Comparable as a global convener in the IBD research community.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/IHU_Infiny
• LinkedInlinkedin.com/company/ihu-infiny

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IHU INFINY - Institut des maladies inflammatoires chroniques de l'intestin